ArticleThe Journal of experimental medicine2020

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19.

Lars M Koenig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.